Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. whilyas

WHILYAS

Wound healing ILYA-style

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 WHILYAS project word cloud

Explore the words cloud of the WHILYAS project. It provides you a very rough idea of what is the project "WHILYAS" about.

15    2011    alarming    sciences    lactic    amputation    tissue    wound    chosen    uppsala    million    acid    debridement    world    lactobacillus    manner    personal    regeneration    delivered    chemokine    patients    endogenously    substantial    treatment    market    approx    countries    possibly    dressings    tackling    2014    drug    bacteria    overuse    group    drugs    bioreactors    small    people    translates    medical    proteins    cheaper    dried    topical    rate    care    heal    segment    industrialized    ulcers    diabetes    candidate    genetically    swedish    diabetic    difficulties    unmet    mortality    healed    cagr    library    wounds    stems    local    4    accelerate    water    university    healthcare    agricultural    alone    chronic    18    act    site    annual    efficiency    human    cancers    least    complications    66    savings    faster    social    limited    ev100    administration    revived    therapeutic    expressing    eur    cxcl12    limb    total    billion    foot    budget    30    healing    mechanical    modified    implying    11    antibiotics    designed    microbiology    prior    innovation    dfus    quality    life    freeze    ilya100tm    immunophysiology    first    spend   

Project "WHILYAS" data sheet

The following table provides information about the project.

Coordinator		 ILYA PHARMA AB 

Organization address
address: DAG HAMMARSKIOLDS VAG 30
city: UPPSALA
postcode: 752 37
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website http://www.ilyapharma.se
 Total cost 2˙992˙575 €
 EC max contribution 2˙992˙575 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ILYA PHARMA AB SE (UPPSALA) coordinator 2˙992˙575.00

Map

 Project objective

The objective of the project is to develop the EV100 drug candidate to heal chronic wounds in patients with diabetes in a better, faster, and cheaper manner than any method available today. We have chosen to target wounds in patients with diabetes, due to a large unmet medical need in this group. Today, 18% of people with diabetes have a chronic wound which translates into at least 6 million people in Europe alone. One of the complications of diabetes, diabetic foot ulcers (DFUs) often result in limb amputation. The mortality rate after an amputation is 30% within the first year, which is similar to several cancers. Even more alarming, treatment is today limited to mechanical debridement, use of different dressings, and a substantial overuse of antibiotics. Industrialized countries spend 2-4% of total healthcare budget on chronic wounds. The market for wound care is EUR 15 billion and the segment of DFUs is in the range of EUR 1.5 billion, with 11% CAGR 2011-2014. We have designed and built genetically modified lactic acid bacteria that accelerate wound healing with a unique efficiency. Human therapeutic proteins endogenously involved in tissue regeneration are continuously delivered on site in wounds by the lactic acid bacteria that act like small local bioreactors. EV100 is one of the candidate drugs in our library using Ilya100TM technology and is Lactobacillus expressing the human chemokine CXCL12. The Lactobacillus are freeze-dried and revived with water just prior to topical administration. The innovation stems from world-leading medical research in immunophysiology and microbiology at Uppsala University and the Swedish University of Agricultural Sciences. With EV100 chronic wounds could possibly be healed approx. 66% faster, implying annual cost savings of EUR 6 billion in the US and Europe and tackling all the personal and social difficulties associated with chronic wounds, increasing the quality of life of patients all around the world.

 Deliverables

List of deliverables.
An updated plan for the exploitation and dissemination of the results Documents, reports 2020-02-11 12:59:43
ORDP - Open Research Data Pilot Open Research Data Pilot 2020-02-11 12:59:43

Take a look to the deliverables list in detail:  detailed list of WHILYAS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Evelina Vågesjö, Emelie Öhnstedt, Anneleen Mortier, Hava Lofton, Fredrik Huss, Paul Proost, Stefan Roos, Mia Phillipson
Accelerated wound healing in mice by on-site production and delivery of CXCL12 by transformed lactic acid bacteria
published pages: 1895-1900, ISSN: 0027-8424, DOI: 10.1073/pnas.1716580115 		Proceedings of the National Academy of Sciences 115/8 2020-02-11
2019 Emelie Öhnstedt, Hava Lofton Tomenius, Evelina Vågesjö, Mia Phillipson
The discovery and development of topical medicines forwound healing
published pages: , ISSN: 1746-045X, DOI: 		Expert Opinion on Drug Discovery 2020-02-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WHILYAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WHILYAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More